REGN4461 - Mibavademab
Sponsors
Regeneron Pharmaceuticals Inc.
Conditions
Generalized LipodystrophyMonogenic obesity
Phase 3
An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene
Not yet recruitingCTIS2024-518674-14-00
Target: 2Updated: 2025-11-06
A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients with Generalized Lipodystrophy
Not yet recruitingCTIS2024-519879-25-00
Target: 2Updated: 2026-03-05